The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.
A California company offering the world's first injectable CBD product is in hot water after the FDA said the IV injections ...
The White House has withdrawn the nomination of David Weldon, a former Florida congressman, to lead the Centers for Disease ...
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
Manitoba's cancer authority has stopped using an infusion pump line — made by a company whose IV pumps have been the subject ...
The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...
Facing the potential loss of hundreds of millions of dollars in federal funding, Duke University is preparing for the worst.
On Wednesday, state officials joined local leaders and private sector partners to celebrate the groundbreaking of Pacific ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Patients with cardiovascular problems often require intravenous (IV) drug administration and fluid management, for which pressure infusion bags are crucial. The increasing number of surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback